Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing

Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells

In order to further define the mechanisms by which polypeptide growth factors regulate gene transcription and cellular growth, expression cloning techniques were used to select human epidermal growth factor (EGF) receptor complementary DNA clones. The EGF 3' coding domain shows striking homology to the transforming gene product of avian erythroblastosis virus (v-erbB). Over-expression of EGF receptors in A431 cell lines correlates with increased EGF receptor mRNA levels and amplification (up to 110 times) of the apparently singular EGF receptor gene. There appear to be three cytoplasmic polyadenylated RNA products of EGF receptor gene expression in A431 cells, one of which contains only 5' (EGF binding domain) sequences and is postulated to encode the secreted EGF receptor-related protein.

A vasopressin-like peptide in the mammalian sympathetic nervous system

Vasopressin was among the first mammalian hormonal peptides to be identified and to have its structure determined. Its only undisputed physiological role is as a circulating neurohypophyseal antidiuretic hormone. Other notable effects of vasopressin on peripheral tissues include contraction of vascular smooth muscle, leading to elevation of blood pressure, and activation of glycogenolysis in liver. It has long been clear that vascular smooth muscle and hepatocytes are relatively insensitive to the low concentrations of vasopressin normally present in the circulation, and the physiological significance of their responses has therefore been in doubt. We now report that a new bioactive and immunoreactive vasopressin-like peptide (VLP) is widely distributed in the sympathetic nervous system of mammals, both in the principal noradrenergic neurones of ganglia and in nerve fibres innervating peripheral tissues. In addition to other peptides described in the mammalian sympathetic nervous system, VLP must be considered as a possible mediator of the non-adrenergic responses to sympathetic activation. Moreover, many of the effects previously attributed to circulating vasopressin may be neurally evoked.

Localization of the polymorphic human calcitonin gene on chromosome 11

A molecular probe containing a 584 base pairs sequence corresponding to part of the human calcitonin mRNA was used for the chromosomal assignment of the calcitonin gene. Restriction endonuclease analysis of DNA from human-Chinese hamster and human-mouse somatic cell hybrids, including some containing a translocation of human chromosomes, placed the calcitonin gene in the p14----qter region of chromosome 11. Analysis of human DNA showed that the calcitonin gene has a polymorphic site for restriction endonuclease TaqI.

Reversed-phase high-performance liquid chromatography: preparative purification of synthetic peptides

Biologically active peptides synthesized by the solid phase methodology of Merrifield were purified by reversed-phase high-performance liquid chromatography using newly developed preparative radially compressed cartridges fitting Waters Assoc . Prep LC 500 liquid chromatograph. Cartridges were handpacked with Vydac C18, C4 or diphenyl derivatized silicas (pore size 300 A) of different particle sizes (10-20 micron). Large scale purification of gram amounts of gonadotropin releasing hormone analogs (agonist and antagonist) as well as amidated human pancreatic tumor growth hormone releasing factor (a 40-peptide) illustrate the resolutive power of this technique applied to the isolation of more than 300 synthetic peptides in our laboratory over the last two years. Difficult separations were achieved by changing supports (C18, C4, diphenyl) as well as mobile phase composition: (triethylammonium phosphate pH 2.25 or 6.5, 0.1% trifluoroacetic acid, ammonium acetate pH 6.5 and acetonitrile). Protected amino acids and peptides amenable to normal-phase chromatography on Vydac spherical underivatized silica were purified economically by the reversed-phase mode. It is understood that this general, convenient and versatile strategy may be applicable to the preparative scale isolation of any other class of compounds usually separated on reversed-phase high-performance liquid chromatography.

Isolation and characterization of human calcitonin gene-related peptide

The rat calcitonin gene has recently been shown to encode a novel peptide (rat calcitonin gene-related peptide, rCGRP) thought to be produced in nervous tissue after tissue-specific RNA processing. This peptide has so far been identified only in rat tissue, by immunocytochemistry and immunoassay. We now report the isolation of a related (89% homology) peptide from human tissue (hCGRP) which we have sequenced using a novel mass spectrometric approach, fast atom bombardment (FAB) mapping. The human peptide differs significantly from the predicted rCGRP structure in four positions in the amino acid sequence (three effecting charge changes), and the presence of a disulphide bridge and an amide, surmised in the rat work, is proven in the hCGRP molecule. hCGRP was present in plasma from 10 patients with medullary thyroid carcinoma (MTC) and in 6 MTC tumours removed at surgery, suggesting the tissue distribution may differ from that in the rat where the peptide is reported to be absent from thyroid tissue. hCGRP is shown to have biological activity and it is possible that its presence in MTC plasma may be responsible for some of the symptoms in this disease.

Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells

Calcitonin gene-related peptide (CGRP) is a putative novel neuropeptide predicted on the basis of alternative RNA processing events of primary transcripts of the calcitonin gene. Distinct mRNAs encoding either calcitonin or CGRP are generated from the calcitonin gene RNA transcript in what appears to be a tissue-specific manner. The predicted peptide has now been detected immunocytochemically in discrete regions of the central and peripheral nervous systems and potent in vivo actions have been reported for centrally and peripherally administered synthetic CGRP. However, so far there is no evidence that CGRP is secreted or released by intact cells. The present experiments investigated the possible secretion of CGRP in vitro using primary dispersed cell cultures of the adult rat trigeminal ganglion, which previously has been found to contain large amounts of CGRP mRNA (ref. 2). We report here that immunoreactive CGRP is spontaneously released by cultured trigeminal ganglion cells and that secretion is stimulated by incubation in high potassium medium in a calcium-dependent fashion. Chromatographic characterization of the secreted CGRP-like immunoreactivity (CGRP-LI) isolated only one molecular form which appears to be similar or identical to the predicted rat CGRP (1-37).

Three tachykinins in mammalian brain

Two polypeptide precursors to the neuropeptide substance P have recently been identified. One of them (β-preprotachykinin) contains amino acid sequences corresponding not only to substance P but also to substance K, a novel, related peptide. A third substance P-like peptide, neuromedin K, has recently been isolated from spinal cord. The existence in vertebrates of three members of the tachykinin family of peptides may account for pharmacological observations suggesting the presence of more than one type of substance P receptor in the nervous system.

Site-specific polyadenylation in a cell-free reaction

A soluble HeLa cell extract accurately polyadenylates RNA transcribed from DNA templates containing the adenovirus L3 polyadenylation site. Regardless of the length of these DNA templates, the major polyadenylated species had 3' termini corresponding to the in vivo site. Polyadenylated RNA appears after an hour lag and only reaches maximum levels after 4 hr of incubation, a time course similar to that of splicing in this extract. Inhibitor studies suggest that the polyadenylation reaction is not coupled to active transcription. Unlike splicing in this extract where exogenous substrate is processed, addition of purified RNA precursor to the reaction does not yield product polyadenylated at L3 but rather results in addition of poly (A) to termini of the precursor. This suggests that part of the specificity of polyadenylation is established by in situ synthesis of RNA. Surprisingly, synthesis of accurately polyadenylated RNA may involve small nuclear ribonucleoprotein particles (snRNPs). The reaction is inhibited by antisera of Sm and U1 RNP specificities as well as antiserum to the nuclear antigen La, but is not inhibited by control serum and anti-(U2)RNP serum.

Antinociceptive activity of salmon calcitonin injected intrathecally in the rat

Salmon calcitonin injected intrathecally in unanesthetized rats produced long-lasting, dose-dependent elevations of nociceptive threshold as measured in the hot plate test. This antinociceptive action was nonopiate in nature as it was uninfluenced by the narcotic antagonists naloxone and MR 1452; moreover, the peptide was still able to raise the nociceptive threshold in morphine-tolerant rats. It is suggested that the spinal cord may represent one of the sites of action for calcitonin-induced antinociception.

Salmon and human calcitonin-like peptides in man

Calcitonin-like peptides have been identified in the serum of normal subjects and of medullary thyroid carcinoma (MTC) patients. Using specific homologous radioimmunoassays (RIA) in combination with reversed-phase high performance liquid chromatography and gel permeation chromatography under denaturing conditions, we have recognized major components which coeluted with human calcitonin-(1-32), PDN-21, a carboxyl-terminal flanking peptide derived from the calcitonin mRNA sequence, and salmon calcitonin-(1-32). An additional 12000 molecular weight peak possibly represents a human calcitonin-PDN-21 polyprotein. In both the human calcitonin-(1-32) (normal value less than 0.043 ngEq/ml; MTC 140 +/- 80 ngEq/ml, mean value +/- SEM) and the PDN-21 (normal value less than 0.050 ngEq/ml; MTC 33.6 +/- 16.5 ngEq/ml) RIAs, serum levels were increased in MTC patients. Circulating levels of the salmon calcitonin-like peptide were indistinguishable between normal subjects (0.038 +/- 0.006 ngEq/ml) and MTC patients (0.037 +/- 0.011 ngEq/ml).

Three different fibronectin mRNAs arise by alternative splicing within the coding region

We report the isolation of cDNA clones for fibronectin from a rat liver library prepared in the expression vector, lambda gt11. Restriction mapping and DNA sequencing of these clones establish the sequence of the C-terminal 35% of rat fibronectin, covering the cell-, heparin-, and fibrin-binding domains. The cell- and heparin-binding regions have homologous repeating sequences. Based on the sequence data and S1 nuclease mapping, we conclude that there are at least three different fibronectin mRNAs in rat liver which differ in coding potential. The three RNAs appear to arise by alternative splicing within the coding region and are probably all encoded by a single gene. The implications of these results for the structure and function of fibronectin and the differences between various types of fibronectin are discussed.

Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide

Alternative splicing of RNA transcripts from the calcitonin gene produces mRNAs that encode different polypeptides. While the mRNA encoding calcitonin predominates in thyroidal 'C' cells, calcitonin gene-related peptide (CGRP) mRNA appears to be the major mRNA component in non-thyroid tissue, including brain. The predicted peptide arising from translation of CGRP mRNA has now been identified immunocytochemically throughout the central and peripheral nervous systems. CGRP, a 37-residue peptide, is distributed in brain pathways subserving sensory, motor and autonomic functions. We report here that CGRP acts in the central nervous system to stimulate selectively noradrenergic sympathetic outflow.